Vir Biotechnology, Inc. rose 1.77% in after-hours trading, following the news that Raymond James initiated coverage on the company with an "Outperform" rating. The company is focused on developing treatments for serious infectious diseases and other conditions, with a pipeline that includes candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV).
Comments
No comments yet